Home › Breast Cancer › Connecticut › New Haven
Breast Cancer clinical trials in New Haven, CT
37 studies for Breast Cancer are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
RecruitingPhase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Yale University School of Medicine, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RecruitingPhase 1
- Yale University - Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RecruitingPhase 1
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
RecruitingPhase 1
- Yale Cancer Center, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RecruitingPhase 3
- Yale Cancer Center ( Site 0060), New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RecruitingPhase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · 7 mi away
- and 2 more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RecruitingPhase 3
- Clinical Trial Site, New Haven
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recruiting
- Yale Cancer Center, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RecruitingPhase 1
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RecruitingPhase 2
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RecruitingPhase 1/2
- Yale Cancer Center, New Haven
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi away
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi away
- and 1 more
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- Smilow Cancer Hospital at Yale New Haven, New Haven
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
RecruitingPhase 2
- Yale University Cancer Center, New Haven
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Recruiting
- Yale Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RecruitingPhase 2
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · 7 mi away
- Smilow Cancer Hospital Care center at Derby, Derby · 8 mi away
- and 1 more
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecruitingPhase 3
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RecruitingPhase 3
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
RecruitingPhase 1
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
RecruitingObservational study
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RecruitingPhase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · 7 mi away
- Smilow Cancer Hospital - Derby, Derby · 8 mi away
- and 1 more
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- Yale Cancer Center, New Haven
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi away
- and 4 more
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Recruiting
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
RecruitingPhase 2
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
RecruitingPhase 3
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RecruitingPhase 1
- Yale University, New Haven
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA111 studies
- Nashville, TN80 studies
- Los Angeles, CA72 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Colorectal Cancer20 studies
- Prostate Cancer20 studies
- Opioid Overdose18 studies
- Alcohol Use Disorder (AUD)17 studies
- Acute Myeloid Leukemia17 studies
- Pancreatic Cancer16 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.